Transcatheter tricuspid-valve replacement is superior to medical therapy alone for patients with severe tricuspid ...

Early transcatheter aortic valve replacement (TAVR) is better than clinical surveillance for reducing the incidence of ...

Heat and Control, in Booths N-6104 and N-6106 at PACK EXPO International, will display its THS/PH210 Series metal detectors ...

In a finding that challenges conventional thinking on when people with failing heart valves but no symptoms should g ...

Edwards Lifesciences Corporation (NYSE: EW) today announced that the EVOQUE system demonstrated superiority compared to medical therapy alone for the one-year primary endpoint of the TRISCEND II trial ...

Market Growth : From USD 695.99 million in 2022 to USD 1.6 billion by 2032 at a CAGR of 8.4% . Energy Efficiency : A primary market driver, supported by stringent regulatory measures on HVAC system ...

Amir Danino, CEO of Innoventric, stated: “Our mission is to revolutionize tricuspid regurgitation care with minimally invasive therapies that significantly improve patient outcomes. The strong backing ...